Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Disorder Related to Cardiac Transplantation
Conditions
Disorder Related to Cardiac Transplantation
Trial Timeline
Dec 1, 2005 → Feb 1, 2010
NCT ID
NCT00377962About Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids is a approved stage product being developed by Novartis for Disorder Related to Cardiac Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00377962. Target conditions include Disorder Related to Cardiac Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00377962 | Approved | Completed |
Competing Products
20 competing products in Disorder Related to Cardiac Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + venlafaxine + placebo | Eli Lilly | Phase 3 | 77 |
| Ketamine + Placebo | Roivant Sciences | Phase 1 | 30 |
| duloxetine | Eli Lilly | Pre-clinical | 23 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Approved | 85 |
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2 | Idorsia | Phase 2 | 47 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine + Placebo | Eli Lilly | Phase 2/3 | 65 |
| LY2422347 + placebo | Eli Lilly | Phase 2 | 52 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine (Cymbalta) | Eli Lilly | Approved | 85 |